EJS ACT-PD, the world’s largest clinical trial for Parkinson’s, is now recruiting
Cure Parkinson’s is excited to announce that the first multi-arm multi-stage clinical trial platform for Parkinson’s in the UK – EJS ACT-PD – is underway, with recruitment now open to people with Parkinson’s. The Edmond J. Safra Accelerating Clinical Trials for Parkinson’s Disease (EJS ACT-PD)...
Learn more
Exenatide-PD3 results published
The full results of the Exenatide-PD3 study, a phase 3 clinical trial of Type 2 diabetes drug exenatide (Bydureon), have now been published. They report that the study unfortunately did not meet its primary or secondary endpoints. The full results of the Exenatide-PD3 study have…
Remembering a loved one with in memory giving
Honouring a loved one’s memory through charitable giving is a deeply meaningful way to celebrate their life and make a lasting difference. In memory donations not only pay tribute to someone special but also provide crucial support for our work to find a cure for…
Prioritising the most promising drugs for Parkinson’s: our new drug screening project
Cure Parkinson’s is excited to announce funding for a preclinical project that aims to test, evaluate and compare drugs that have the potential to slow Parkinson’s progression. Established by Cure Parkinson’s, in collaboration with Van Andel Institute (VAI), the International Linked Clinical Trials (iLCT) committee…
Limited edition album ‘Think Loud’ supports Cure Parkinson’s
Music legends from the worlds of rock and folk have come together to create an exclusive double album to help raise funds and awareness for Cure Parkinson’s. Kindred Spirit have teamed up with musicians including Leo Sayer, John Cooper Clarke, Richard Thompson and Hugh Cornwell…
Cure Parkinson’s Fundraising Heroes: December 2024
2024 was a phenomenal year of fundraising for Cure Parkinson’s, and we’d like to say a huge thank you to everyone who helped raise vital funds and awareness for our research! We can’t wait to see what you – our incredible supporters – will do…